Factor XIIa (Coagulation Factor XIIa)

Activated form of factor XII. In the initial event in the intrinsic pathway of blood coagulation, kallikrein (with cofactor HIGH MOLECULAR WEIGHT KININOGEN) cleaves factor XII to XIIa. Factor XIIa is then further cleaved by kallikrein, plasmin, and trypsin to yield smaller factor XII fragments (Hageman-Factor fragments). These fragments increase the activity of prekallikrein to kallikrein but decrease the procoagulant activity of factor XII.

Also Known As:

Networked: 108 relevant articles (1 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Nolte, Marc W: 6 articles (01/2022 - 11/2012)
2.	Kleinschnitz, Christoph: 4 articles (01/2017 - 02/2013)
3.	Grundt, Heidi: 4 articles (12/2009 - 04/2003)
4.	Panousis, Con: 3 articles (01/2022 - 01/2016)
5.	Pragst, Ingo: 3 articles (01/2022 - 01/2016)
6.	Kaplan, Allen P: 3 articles (11/2020 - 03/2010)
7.	Morrissey, James H: 3 articles (01/2017 - 12/2011)
8.	Sirén, Anna-Leena: 3 articles (01/2017 - 02/2013)
9.	Smith, Stephanie A: 3 articles (01/2017 - 11/2010)
10.	Dickneite, Gerhard: 3 articles (01/2016 - 11/2012)

Related Diseases

1.	Thrombosis (Thrombus) 01/01/2016 - "This study aimed to further assess the antithrombotic efficacy of the activated factor XII (FXIIa) inhibitor, rHA-Infestin-4, in several thrombosis models. " 01/01/2017 - "Factor XIIa as a Novel Target for Thrombosis: Target Engagement Requirement and Efficacy in a Rabbit Model of Microembolic Signals." 05/01/2015 - "Inhibition of factor XIIa, a new approach in management of thrombosis." 12/08/2022 - "Factor XIIa (FXIIa) is a promising target for developing new drugs that prevent thrombosis without causing bleeding complications. " 08/11/2016 - "Inhibition of factor XIIa (FXIIa) provides thrombus protection without bleeding complications. "
2.	Inflammation (Inflammations) 11/01/2012 - "The purpose of this study was use molecular imaging targeting coagulation pathway and inflammation to better understand the pathophysiology of silent brain ischemia (SBI) and monitor the effects of factor XIIa inhibition. " 12/01/2006 - "Activated Factor XII (XIIa) is believed to participate in a number of pathophysiological processes including inflammation, thrombosis and fibrinolysis. " 04/01/2019 - "Activated Factor XII exhibits other activities, in that it can activate complement and provoke inflammation, contributing to innate immunity. " 10/01/2018 - "Factor XIIa (FXIIa) was one of the first coagulation factors implicated in inducing both humoral and cellular responses and is therefore considered a prime new therapeutic target in immune-mediated inflammation. " 11/01/1988 - "Since Factor XIIa is generated during inflammation, we studied the effect of XIIa on Fc gamma RI. "
3.	Hereditary Angioedemas 01/01/2022 - "Prophylaxis with anti-activated factor XII for hereditary angioedema." 01/01/2022 - "Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial." 01/01/2023 - "Garadacimab (CSL312), a novel, fully-human monoclonal antibody that inhibits activated factor XII (FXIIa), is being studied for the prevention of hereditary angioedema attacks. " 02/15/1990 - "Interactions of C1(-)-inhibitors from normal persons and patients with type II hereditary angioneurotic edema with purified activated Hageman factor (factor XIIa)." 03/01/2010 - "C1 inhibitor deficiency causes dysregulation of the plasma bradykinin-forming cascade with overproduction of bradykinin due to uninhibited effects of activated factor XII and plasma kallikrein. "
4.	Hypertension (High Blood Pressure) 04/01/2020 - "The effects of two types of renin-angiotensin system inhibitors on the hypertension induced by new pressor protein associated with beta-factor XIIa in rats." 07/01/2014 - "Coagulation factor XIIa-kinin-mediated contribution to hypertension of chronic kidney disease." 01/06/2022 - "By potentiating thrombin and factor-XIIa and inhibiting plasmin, BQTX induces acute hypertension, blood coagulation and hypokinesia. " 04/01/2020 - "New pressor protein (NPP) is a human plasma enzyme, which is structurally related to the beta-fragment of activated factor XII. The present study aimed to compare the effects of angiotensin converting enzyme inhibitors (captopril) and angiotensin type 1 receptor blocker (losartan) on the hypertension induced by NPP injection in normal (sham-2NX) and bilaterally nephrectomized rats (2NX). "
5.	Coronary Disease (Coronary Heart Disease) 09/01/2002 - "Previous studies have shown an increased risk of coronary heart disease with increased levels of activated factor XII (FXIIa). " 10/24/2000 - "The relations of plasma activated factor XII (FXIIa) concentration and a common polymorphism (C46T) of the factor XII gene with hemostatic status and risk of coronary heart disease (CHD) were examined by prospective surveillance. " 10/24/2000 - "Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men." 10/01/2011 - "We measured baseline peripheral blood concentrations of soluble E-selectin, factor XIIa, thrombin-antithrombin III complex and plasminogen activator inhibitor-1 in 86 patients with Type 2 diabetes free of known coronary heart disease. "

Related Drugs and Biologics

1.	Factor XIa (Coagulation Factor XIa)
2.	Factor XII (Hageman Factor)
3.	Kallikreins (Kallikrein)
4.	High-Molecular-Weight Kininogen (Kininogen, High Molecular Weight)
5.	Plasma Kallikrein
6.	Peptide Hydrolases (Proteases)
7.	Enzymes
8.	Proteins (Proteins, Gene)
9.	Monoclonal Antibodies
10.	Antithrombins

Related Therapies and Procedures

1.	Therapeutics
2.	Thrombolytic Therapy
3.	Membrane Oxygenators (Membrane Oxygenator)